What is Delcath Systems?
Delcath Systems, Inc. is dedicated to advancing the treatment of primary and metastatic liver cancers through its proprietary hepatic delivery system. The company's core technology facilitates the administration of high-dose chemotherapy, specifically melphalan hydrochloride, directly to the liver. This targeted approach aims to maximize therapeutic efficacy while potentially minimizing systemic side effects. In Europe, the company offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan brand. Founded in 1988 and headquartered in New York, NY, Delcath Systems operates within the critical intersection of interventional oncology and advanced drug delivery.
How much funding has Delcath Systems raised?
Delcath Systems has raised a total of $108.5M across 3 funding rounds:
Stock Offering
$7.2M
Other Financing Round
$85M
Series E
$16.3M
Stock Issuance/Offering (2000): $7.2M, investors not publicly disclosed
Other Financing Round (2023): $85M led by Vivo Capital, Logos Capital, and BVF Partners
Series E (2024): $16.3M, investors not publicly disclosed
Key Investors in Delcath Systems
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
Logos Capital
Logos Capital is a Miami-based impact investment firm dedicated to providing financial solutions that address global challenges. Established in 2011, the firm offers services in investment banking, private equity, trade finance, and project finance, targeting companies with positive social and environmental impacts.
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies.
What's next for Delcath Systems?
The recent major strategic investment signifies Delcath Systems' progression into a more mature phase of its corporate lifecycle, likely aimed at scaling operations, expanding clinical trials, or further commercializing its liver-directed therapies. This enterprise-level backing provides the necessary capital to pursue strategic growth initiatives and solidify its market position in the competitive oncology landscape. Future developments may include broader market penetration, potential regulatory approvals in new territories, and continued innovation in its drug delivery platform.
See full Delcath Systems company page
